Clinical trial
AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
NCT00493441 · Vertex Pharmaceuticals Incorporated, Industry · Terminated
Key facts
| NCT number | NCT00493441 |
|---|---|
| Title | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer |
| Official title | A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | AVN944 |
| Enrollment | 28 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jun 28, 2007 |
| Last update posted | Sep 30, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: